This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

Sponsored by BioCryst Pharmaceuticals

About this trial

Last updated 2 years ago

Study ID

BCX7353-312

Status

Active, not recruiting

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
12+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 4 years ago

What is this trial about?

This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.

What are the Participation Requirements?

Key Inclusion Criteria:

- Males and females currently enrolled in BioCryst-sponsored Study 302 or 204

- Able to provide written informed consent.

- Would benefit from continued berotralstat treatment

- Acceptable effective contraception

Key Exclusion Criteria:

- Pregnancy or breast-feeding

- Any condition or situation, including medical history that, in the opinion of the
investigator or sponsor, would interfere with the subject's safety or ability to
participate in the study

- Use of other medications for long-term prophylaxis of HAE attacks at the Baseline
visit or any time during the study.

- Use of any other investigational medicinal product at the Baseline visit or any time
during the study.

Locations

Location

Status